July 2024

Here to help: developing your career

Dan Nimmo, IBMS Head of Communications, highlights the robust array of networking opportunities the IBMS offers members that are designed to foster career growth and professional development.

Remember and celebrate

We hear from a special event the IBMS held at the Imperial War Museum on 6 June.

Trending: Biomedical Science Day

We look back at this year’s Biomedical Science Day – the largest annual celebration of biomedical scientists and laboratory staff in the UK.

Advanced practice: facilitators and barriers

Aimee Pinnington, Lecturer in Biomedical Science at Keele University, with an update on her research into education, training and development pathways.

Robust verification

Dan Kelly, POCT Hub Lead at Spire Healthcare, looks at POCT verification processes, from equipment checks to reviewing decision levels and confirmatory testing in hub laboratories.

Phenotypic plasticity in melanoma: the impact on management strategies

Dr Ghada Elayat looks at the role of epithelial–mesenchymal transition in cancer and the implications for melanoma development.

The big question: Are we entering a new era in which mRNA vaccines are the future?

In May, AstraZeneca began the worldwide withdrawal of its COVID-19 vaccine, due to a “surplus of updated vaccines” that target new variants. Then in June, Moderna announced positive late-stage trial results for its single COVID/flu combination vaccine, mRNA-1083. On the back of this, we look at the future impact of mRNA vaccines.

Predicting the return of breast cancer

Dr Isaac Garcia-Murillas discusses a new blood test that can predict if breast cancer will return years before the disease shows on scans.

News in brief: July 2024

This month's top news in brief stories

AI search engines put to the test

Four proposed state-of-the-art image search engines for automating search and retrieval of digital histopathology slides were found to be of inadequate performance for routine clinical care, US research suggests.

Sarcoma relapse risk reduced by 43%

A global team of researchers has announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults.

Top